Abiomed to Highlight Importance of Optimal PCI Treatment to Improve Outcomes for High-Risk Patients at TCT 2019
DANVERS, Mass.--(BUSINESS WIRE)--Sep. 17, 2019-- Abiomed (NASDAQ:ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31st Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco from September 25-29. During the conference, Abiomed will also offer hands-on training to help physicians improve access and closure skills and patient management expertise to achieve improved outcomes.
Optimal Outcomes in Complex Patients Are Driven by Enabling Complete Revascularization and Reducing Risk of Acute Kidney Injury
During two breakfast symposia hosted by Abiomed, interventionalists and fellows will present cases and best practices using Impella devices to improve outcomes.
A symposium on Thursday, September 26, will feature best practices for using percutaneous mechanical circulatory support to enable complete revascularization in complex and sick patients.
The schedule for this symposium is below:
Treating the Complex Patients: Impella Enabled Complete Revascularization Thursday, September 26 6:30-7:45 a.m. PDT
Moscone South, Level 2, Room 205-206
Chair: William O’Neill, MD
Protected PCI: A Contemporary Look at Clinical Data from cVAD Jeff Popma, MD
The Value of Complete Revascularization in a Single Setting
Raj Patel, MD
Driving Quality in PCI: The Benefits of Complete Revascularization for Improvements in Ejection Fraction and Patient Quality of Life Ehtisham Mahmud, MD
A second symposium on Friday, September 27, will highlight the most interesting and complex cases submitted by fellows around the globe. Attendees will learn techniques used for the procedures and how to use hemodynamic support to achieve optimal outcomes.
The schedule for this symposium is below:
Management of Complex PCI Patients: Award Winning Case Presentations
Friday, September 27 6:30-7:45 a.m. PDT
Moscone South, Level 2, Room 201-202
Co-Chairs: David Wohns, MD and George Dangas, MD
Panelists: Ayaz Rahman, MD; Justin Levisay, MD; Amir Kaki, MD
Successful Resuscitation of Acute Cardiogenic Shock Presenting as Ventricular Fibrillation via Bipella Approach Yashwant Agrawal, MD
Double Indication for Impella CP: High Risk Percutaneous Coronary Intervention (PCI) and Acute Myocardial Infarction Complicated by Cardiogenic Shock (AMICS) Rafael C. Ferreira, MD
IMPELLA Facilitated IVUS-Guided Left-Main with Double CTO Revascularization in NSTEMI With Severe LV Impairment and Severe Ischemic Mitral Regurgitation Kalaivani Mahadevan, MD
Improving Outcomes Through Hands-On Training for Interventionalists
Treatment of Cardiogenic Shock
Faculty: David A. Baran, MD; Mir Babar Basir, DO; Arthur Garan, MD; Maximilian Halbe, Director MCS; Colin Hirst, MD; Perwaiz M. Meraj, MD, FSCAI; L. Christian Napp, MD
Tips and Tricks for CHIP/Complex PCI
Faculty: Dimitrios Bliagos, MD; Ronald Caputo, MD; Jon C. George, MD; Annapoorna Kini, MD; Kintur A. Sanghvi, MD, FACC, FSCAI; Goran Stankovic, MD, PhD; Jason Wollmuth, MD
Physicians are also invited to visit booth #1727 to learn about Impella CP with SmartAssist, experience Impella Connect, practice their skills on a simulator, learn about new metrics and algorithms, and have their questions answered by advanced Impella trainers.
Impella CP with SmartAssist is the latest technological development for the Impella platform and is designed to improve patient outcomes with advanced algorithms and simplified patient management. SmartAssist has been commercially available in the U.S. since May, and launched in Europe in August.
In all, Impella devices will be featured in more than 30 presentations at TCT 2019, focusing on topics such as:
STEMI, Cardiac Arrest, and Cardiogenic Shock: Part 1
Featured presentation: LV Unloading to Reduce Infarct Size: Rationale, Completed Studies, and Ongoing Trials Navin Kapur, MD Thursday, September 26 4:45 p.m. PDT
STEMI, Cardiac Arrest, and Cardiogenic Shock: Part 2
Featured presentation: While Awaiting More Clinical Trial Data: Real-World Approaches to Cardiogenic Shock and Hemodynamic Support Alex Truesdell, MD Friday, September 27 4:20 p.m. PDT
High Impact Clinical Research: Management of Cardiogenic Shock
Featured presentation: Impact of Right Ventricular Dysfunction in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Mir Babar Basir, DO Saturday, September 28 10:15 a.m. PDT
Innovation and Keynote Theater
Investors are invited to join Abiomed’s annual investor meeting on Thursday, September 26. Jeff Popma, MD, will present on: Treating the Complex Patients: Impella Enabled Complete Revascularization. To request attendance, please email email@example.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are U.S. FDA PMA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. The Impella 2.5, Impella CP, Impella CP with SmartAssist™, Impella 5.0® and Impella LD® are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days. The Impella 5.5™ heart pump is CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 30 days. The Impella RP is CE marked to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery, or refractory ventricular arrhythmia.
To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.impella.com.
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella BTR, Impella 5.5, Impella ECP, CVAD Study, and SmartAssist are pending trademarks of Abiomed, Inc.
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.